|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5 Pt 1
|
|
pubmed:dateCreated |
1997-12-8
|
|
pubmed:abstractText |
An excess of androgen is believed to contribute to development of acne in some patients. Because oral contraceptives (OCs) may reduce the active androgen level, hormonal therapy with OCs has been used successfully to treat patients with acne, although this treatment has previously not been studied in placebo-controlled trials.
|
|
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/ACNE,
http://linkedlifedata.com/resource/pubmed/keyword/Americas,
http://linkedlifedata.com/resource/pubmed/keyword/Case Control Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Trials,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents--therapeutic use,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Methods--therapeutic...,
http://linkedlifedata.com/resource/pubmed/keyword/DERMATITIS,
http://linkedlifedata.com/resource/pubmed/keyword/Developed Countries,
http://linkedlifedata.com/resource/pubmed/keyword/Diseases,
http://linkedlifedata.com/resource/pubmed/keyword/Ethinyl Estradiol--therapeutic use,
http://linkedlifedata.com/resource/pubmed/keyword/Family Planning,
http://linkedlifedata.com/resource/pubmed/keyword/North America,
http://linkedlifedata.com/resource/pubmed/keyword/Northern America,
http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives...,
http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives...,
http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives--therapeutic use,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Research Report,
http://linkedlifedata.com/resource/pubmed/keyword/Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Treatment,
http://linkedlifedata.com/resource/pubmed/keyword/United States
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Contraceptives, Oral, Combined,
http://linkedlifedata.com/resource/pubmed/chemical/Contraceptives, Oral, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Ethinyl Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Norgestrel,
http://linkedlifedata.com/resource/pubmed/chemical/norgestimate,
http://linkedlifedata.com/resource/pubmed/chemical/norgestimate, ethinyl estradiol...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0190-9622
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
746-54
|
|
pubmed:dateRevised |
2009-11-6
|
|
pubmed:otherAbstract |
PIP: To evaluate the efficacy of a triphasic combined oral contraceptive (OC) in the treatment of moderate acne vulgaris, 231 healthy US volunteers 15-49 years of age with this dermatologic condition were enrolled in a phase III, multicenter, double-blind, placebo-controlled clinical trial. Each month for 6 months, subjects (n = 110) received either 3 consecutive weeks of Ortho Tri-Cyclen (containing a fixed dose of 0.035 mg of ethinyl estradiol and 0.180, 0.215, and 0.250 mg of norgestimate) followed by 7 days of inactive drug or placebo. The OC group showed significantly greater improvement than controls on all efficacy measures. The mean decrease in inflammatory lesion count from baseline to the sixth cycle was 11.8 (62.0%) among cases and 7.6 (38.6%) in controls, while the mean decrease in total lesion count was 29.1 (53.1%) versus 14.1 (26.8%) in the OC and placebo groups, respectively. In the investigator's global assessment, 93.7% of women in the treatment group and 65.4% of controls were rated as improved at the end of the study. Similarly, more cases than controls considered their acne "improved" at the study's end and expressed a preference for this therapy over other forms of acne treatment. These findings indicate that treatment of moderate acne vulgaris with a low-dose triphasic OC is safe and effective in women with no contraindications to OC use.
|
|
pubmed:meshHeading |
pubmed-meshheading:9366821-Acne Vulgaris,
pubmed-meshheading:9366821-Adolescent,
pubmed-meshheading:9366821-Adult,
pubmed-meshheading:9366821-Contraceptives, Oral, Combined,
pubmed-meshheading:9366821-Contraceptives, Oral, Synthetic,
pubmed-meshheading:9366821-Double-Blind Method,
pubmed-meshheading:9366821-Ethinyl Estradiol,
pubmed-meshheading:9366821-Female,
pubmed-meshheading:9366821-Headache,
pubmed-meshheading:9366821-Humans,
pubmed-meshheading:9366821-Middle Aged,
pubmed-meshheading:9366821-Nausea,
pubmed-meshheading:9366821-Norgestrel,
pubmed-meshheading:9366821-Patient Participation,
pubmed-meshheading:9366821-Prospective Studies,
pubmed-meshheading:9366821-Respiratory Tract Infections,
pubmed-meshheading:9366821-Treatment Outcome
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
|
|
pubmed:affiliation |
Dermatology Research Associates, Inc., Cincinnati, OH 45230, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
